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Available online 10 August 2017Aims: In STEMI patients, success of reperfusion of primary PCI predicts cardiac remodeling and clinical outcome.
This success may depend on inﬂammation. We aimed to investigate the association between inﬂammation and
reperfusion success, left ventricular function and long-term mortality in STEMI patients.
Methods: In 376 consecutive STEMI patients of the GIPS-III trial hs-CRP levelsweremeasured at baseline, 2weeks,
7 weeks and 4 months post-PCI. Myocardial blush grade was used to determine success of myocardial reperfu-
sion. In multivariate models sex, age, hs-CRP levels at baseline, NT-proBNP levels at baseline, ischemia time,
heart rate, TIMI ﬂow, and CK, CKMB and troponin AUC were included. Follow-up was complete until 4 months.
Results: Baseline hs-CRP levelswere 2.1mg/l (IQR 0.5–4.2mg/l). hs-CRP levelswere associatedwith impaired re-
perfusion (OR 1.239, 95% CI 1.006–1.527) and remained higher compared to patientswith normal reperfusion up
to 2months after PCI (hs-CRP 1.9mg/l (IQR 0.9–3.7mg/l) versus 1.5mg/l (IQR 0.7–2.7mg/l), p= 0.041). Inmul-
tivariate analysis baseline hs-CRP levels remained independently associated with impaired reperfusion. In pa-
tients with impaired reperfusion, hs-CRP and NT-proBNP levels remained higher during 4 months of follow-
up. No correlation was observed between hs-CRP at baseline and left ventricular function at 4months. The num-
ber of events was small and we observed no differences in mortality.
Conclusion: Increased hs-CRP levels at presentation are associatedwith impairedmicrovascular reperfusion after
PCI in STEMI patients and remain higher until 2 months follow-up.
© 2017 Published by Elsevier Ireland Ltd.Keywords:
High sensitivity C-reactive protein
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Reperfusion injury
ST-elevation myocardial infarction1. Introduction
In patients with acute myocardial infarction (AMI) morbidity and
mortality remains high despite advances in treatment like timely reper-
fusion of coronary stenosis by primary percutaneous coronary interven-
tion (PCI). After AMI left ventricular function is often impaired due
to impaired left ventricular remodeling and results in heart failure
(HF) [1–3]. Inﬂammation is considered to play a substantial role in the
pathophysiological process of cardiac remodeling [4,5]. AMI triggers a
systemic acute-phase response, in which neutrophils and monocytes/
macrophages track to the infarcted region of the heart [2]. Epidemiolog-
ical studies suggest that circulating concentrations of inﬂammatory
markers, such as C-reactive protein (CRP) are associated with subse-
quent risk of atherosclerosis formation, coronary heart disease (CHD)
and cardiac remodeling. In the setting of an AMI elevated CRP levels
on admission are associated with impaired myocardial reperfusion asn, University Medical Center
RBGroningen, TheNetherlands.
arst).
ability and freedom from bias ofdepicted by lower Thrombolysis in Myocardial Infarction (TIMI) ﬂow
grades [6–9]. A clear difference in CRP patterns between different
forms of acute coronary syndrome (ACS) was previously described in
the early days after admission [10]. Currently, sparse data is available
about time course of CRP levels and its associationwith reperfusion suc-
cess after AMI. The aim of this study was to investigate the association
between inﬂammation, as determined by high sensitivity C-reactive
protein (hs-CRP), and reperfusion success, left ventricular function
and long-termmortality in patientswith ST elevationmyocardial infarc-
tion (STEMI).
2. Methods
2.1. Study population and design
We included all patients participating in the GIPS-III trial. This trial was designed to
evaluate the effect of metformin treatment on preservation of left ventricular function in
STEMI patientswithout diabetes. Details on thedesign of theGIPS-III trial have been reported
previously [11]. In brief, all patients admitted to the University Medical Center Groningen
between January 1st, 2011, and May 26th 2013, via the STEMI protocol were considered
eligible for the trial. Inclusion criteria were age older than 18 years, the presence of STEMI,
and primary PCI with implantation of at least 1 stent with a diameter of at least 3 mm
resulting in TIMI ﬂow grade 2 or 3 post PCI. Major exclusion criteria were previous
Table 1










Age, mean (SD), years 60.2 ± 12.4 58.1 ± 11.3 0.056
Female sex – no. (%) 27 (23.5) 67 (25.6) 0.665
BMI, mean (SD), kg/m2 27.0 ± 4.0 27.0 ± 3.7 0.450
Cardiovascular related history – no. (%)
Hypertension 31 (27.0) 80 (30.5) 0.483
Dyslipidemia 69 (60.0) 169 (64.5) 0.404
Current smoking 59 (51.3) 148 (56.5) 0.554
Stroke 1 (0.9) 2 (0.8) 0.915
Peripheral artery disease 0 0 –
Previous PCI 2 (1.7) 2 (0.8) 0.395
Blood pressure, mean (SD) mm Hg
Systolic 135 ± 23 134 ± 24 0.456
Diastolic 84 ± 14 85 ± 15 0.719
Heart rate, mean (SD), beats/min 78 ± 18 75 ± 15 0.056
Ischemia time, median (IQR), min 190 (125–326) 145 (102–229) 0.001
Single vessel disease – no. (%) 79 (69) 177 (68) 0.827
Infarct-related artery TIMI
ﬂow – no. (%)
0.005
Preintervention grade 0.011
0 72 (63) 135 (52)
1 11 (10) 16 (6)
2 20 (17) 46 (18)
3 12 (10) 65 (25)
Post intervention grade 0.000
2 31 (27) 2 (1)
3 84 (73) 260 (99)
Laboratory values at admission
CK, median (IQR), U/l 138 (93–196) 110 (80–178) 0.015
Myocardial band of CK,
median (IQR), U/l
17 (14–25) 15 (12−22) 0.001
Troponin, median (IQR), ng/l 76 (30−230) 43 (22–99) 0.001
Creatinine, median (IQR),
umol/l
73 (61–80) 71 (63–81) 0.911
NT-proBNP, median (IQR), ng/l 82 (42–274) 78 (37–156) 0.023
Glucose, median (IQR), mmol/l 7.7 (6.9–9.4) 8.5 (7.2–10.1) 0.327
HbA1c, median (IQR), % 6 (5.7–6.2) 5.9 (5.7–6.1) 0.086
Peak values
Peak CK, median (IQR), U/l 1755 (811–3610) 1123 (440–2882) 0.002
Peak myocardial band of CK,
median (IQR), U/l
216 (103–419) 142 (57–300) 0.002






AUC CK, median (IQR),
U/l sec ∗ 10−8
1.43 (0.58–2.60) 0.83 (0.35–1.83) 0.000
AUC myocardial band of CK,
median (IQR), U/l sec ∗ 10−8
0.13 (0.07–0.26) 0.09 (0.04–0.17) 0.000
AUC troponin, median (IQR),
ng/l sec ∗ 10−8
3.00 (1.15–6.64) 1.62 (0.56–3.91) 0.000
Blood count and biochemistry
Leucocytes (10e9/l) 12 (9–14) 11 (8–13) 0.012
Thrombocytes (10e9/l) 240 (203–276) 232 (204–267) 0.315
Neutrophils (10e9/l) 9 (7–11) 7 (5–9) 0.000
Lymphocytes (10e9/l) 2 (1–2) 2 (2–3) 0.061
N/L ratio 5.19 (2.92–7.34) 3.32 (2.19–5.36) 0.001
Data are expressed as mean ± standard deviation (SD), median (interquartile range
(IQR)), or as number (%). AUC = Area under the curve; BMI = Body Mass Index; TIMI =
Thrombolysis in Myocardial Infarction; CK = creatine kinase; NT-proBNP = N-terminal
pro brain natriuretic peptide; HbA1c = glycated hemoglobin; N/L = neutrophil/
lymphocyte.
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vere renal dysfunction, and standard contraindications for magnetic resonance imaging
(MRI) [12]. The study protocol of the GIPS-III trial was in accordance with the Declaration
of Helsinki and was approved by the local ethics committee (Groningen, the Netherlands)
and national regulatory authorities. Informed consent was obtained for inclusion of the
patients.
2.2. Data collection
On admission, standard laboratory assessment was performed and standard physical
examination parameters were measured according protocol. Patients were seen in the
outpatient clinic 2 weeks, 7 weeks, 4 months, and one year after discharge.
During hospitalization, blood was sampled at baseline (initial admission) and at 3, 6,
9, 12, and 24 h after PCI to monitor values of cardiac enzymes and high sensitive troponin.
Less frequently during hospitalization and at every visit to the outpatient clinic hemoglo-
bin, leucocytes (including neutrophils, lymphocytes), platelets, glucose, hs-CRP and
N-terminal pro B-type natriuretic peptide (NT-proBNP) were determined. Furthermore,
during PCI, 24 h after PCI, and at every visit to the outpatient clinic, blood samples for
additional analyses were collected [11]. The incidence of major adverse cardiac events
(MACE; the combined end point of death, reinfarction, or target-lesion revascularization)
was recorded until 4 months.
hs-CRP was assayed by nephelometry with a lower limit of 0.175 mg/l (BNII N; Dade
Behring, Marburg Germany). A hs-CRP level below 1mg/l was considered as normal [13].
Leucocytes were determined on the XE2100 – system (Sysmex, Japan). As the neurophil/
lymphocyte ratio is associated with cardiovascular outcomes, we calculated this ratio
as well [14]. NT-proBNP levels were examined (Roche (Modular, Germany)), as NT-
proBNP is known as a biomarker for the development of HF and inﬂammation is thought
to play a role in the development of HF [15]. Furthermore, we calculated the ratio between
hs-CRP andNT-proBNP levels evaluatingwhether these ratioswould bedifferent between
reperfusion groups.
2.3. Myocardial blush grade
Myocardial blush grade (MBG) represents an angiographic measurement of myocar-
dial perfusion [16]. It reﬂects myocardial response to ischemic injury and reperfusion.
MBG was categorized as follows: 0 = no myocardial blush, or contrast density; 1 =
minimal myocardial blush; 2 = moderate myocardial blush but less than that obtained
during angiography of a contralateral or ipsilateral non-infarct-related coronary artery;
3 = normal myocardial blush comparable to that obtained during angiography of a
contralateral or ipsilateral non-infarct-related coronary artery [17]. The patients were
categorized as having normal (MBG 3) versus impaired (MBG 0–2) reperfusion. Coronary
angiograms were analysed by two physicians blinded to clinical data.
2.4. Statistical analysis
Continuous variableswere summarized asmean±standarddeviation if normally dis-
tributed ormedian and interquartile range if skewed. Discrete variableswere presented as
frequencies and percentages. To compare groups, we used Student's t-test for normally
distributed continuous variables, Mann–Whitney U test for skewed continuous variables,
Chi-square and Fisher's exact test for categorical variables. In order to be able to compare
hs-CRP levels within reperfusion groups (between consecutive time points) and between
reperfusion groups on the same time points, we usedmixedmodel analysis. Wemodeled
hs-CRP using a random intercepts regressionmodel in terms ofMBG and time points. Area
under the curve (AUC) and peak values were calculated over the ﬁrst 72 h post-PCI using
the trapezoidmethod as previously described. No curvewas calculated for patients having
b2measurements or onlymeasurementswith a timespan of b10h. Inmultivariatemodels
(logistic regression) for impaired reperfusion (impaired vs. normal), sex, age, hs-CRP
levels at baseline, NT-proBNP levels at baseline, ischemia time, heart rate, TIMI ﬂow
(pre- and postintervention), and CK, CKMB and troponin AUC were included. Statistical
signiﬁcance was considered at a 2-tailed p-value of b0.05. Statistical analyses were
performed with Stata version 13.0 (StataCorp).
3. Results
3.1. Study population
From 1 January 2011–26May 2013, 376 out of 1473 patients admit-
ted to the hospital via the STEMI protocol were included in the analysis
[12]. Baseline characteristics are presented in Table 1.
Clinical characteristics did not signiﬁcantly differ between patients
with impaired and normal reperfusion. The average age was 59 ±
12 years and 25% were female. Time between ﬁrst complaints and
catheterization, i.e. ischemia time, was longer in patients with impaired
reperfusion than in patients with normal reperfusion. Levels of CK, CK-
MB, andNT-proBNP at admissionwere higher in patientswith impaired
reperfusion than in patients with normal reperfusion. Furthermore,levels of leucocytes and neutrophils, and the neutrophil/lymphocyte
ratio were higher in patients with impaired reperfusion (Table 1).3.2. Temporal course of hs-CRP
hs-CRP levels are presented in Fig. 1A and B. Levels of hs-CRP
decreased over time in both groups. Patients with normal reperfusion
had lower hs-CRP levels at baseline, 2 weeks, and 7 weeks compared
53H.E. Groot et al. / International Journal of Cardiology 248 (2017) 51–56to patients with impaired reperfusion. At 4 months, hs-CRP levels were
not signiﬁcantly different.3.3. hs-CRP and associations
hs-CRP levels at baseline were positively correlated with leucocyte
levels at baseline, NT-proBNP levels at baseline, and ischemia time
(r=0.19, p=0.001; r=0.21, pb 0.001; r=0.22, p b 0.001, respectively)
and negatively correlated with myocardial reperfusion (r =−0.12, p =
0.035) (Table 2). After multivariate adjustment, higher hs-CRP levels
at baseline remained positively associated with impaired reperfusion.
Higher infarct-related artery TIMI ﬂow (postintervention) had a negative
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Fig. 1.hs-CRP levels andNT-proBNP levels over time in376 patientswith impaired reperfusion a
levels within and between reperfusion groups. Data are presented as mean and standard error
impaired reperfusion between the lowest (baseline 0–1 mg/l, 2 w 0–0.9 mg/l, 7 w 0–0.8 mg/l,
4 m N 2.5 mg/l) of hs-CRP levels. Fig. 1B and C depict hs-CRP and NT-proBNP levels betwee
reperfusion groups between consecutive time points. hs-CRP remained signiﬁcantly higher
higher in these patients (Fig. B). Fig. C depicts a combination of Figs. A and B in order to show
decreased signiﬁcantly in both reperfusion groups between 2 and 7 weeks, whereas NT-pro BN3.4. Temporal course of hs-CRP, NT-proBNP, and CRP/NT-proBNP ratio
Levels of NT-proBNP were higher in patients with impaired re-
perfusion in time (Fig. 1C). NT-proBNP increased in both groups
between baseline and two weeks, these levels decreased thereafter.
At 4 months NT-proBNP levels remained higher in patients with
impaired reperfusion. Furthermore, ratio between hs-CRP and NT-
proBNP levels over time did not signiﬁcantly differ between groups
(Supplemental Fig. 1).
3.5. Outcomes
Clinical outcomes at 4 months did not signiﬁcantly differ between




ndnormal reperfusion.Mixedmodel analysiswasused to compare hs-CRP andNT-proBNP
of the mean (SEM). NS = not signiﬁcant. Fig. 1A depicts the proportion of patients with
4 m 0–0.7 mg/l) and highest quartile (baseline N 4.3 mg/l, 2 w N5.0 mg/l, 7 w N 3.3 mg/l,
n the reperfusion groups on the same time points. Fig. 1D shows the decrease within
in patients with impaired reperfusion for 7 weeks (Fig. A). NT-proBNP levels were also
the parallelism of the biomarkers in both reperfusion groups. Furthermore, hs-CRP levels
P levels differed between all consecutive time points (Fig. C).
Table 2
Correlation between hs-CRP at baseline and other variables.
Characteristic hs-CRP at baseline p-Value
Leucocytes at baseline 0.19 0.001
NT-proBNP at baseline 0.21 0.000
Ischemic time 0.22 0.000
MBG (0,1,2,3) at baseline −0.12 0.035
MBG (reduced vs. normal) at baseline −0.13 0.029
Infarct size (%) at 4 months −0.04 0.533
LVEF (%) at 4 months −0.06 0.353
hs-CRP=high sensitivity C-reactive protein; NT-proBNP=N terminal probrain natriuretic
peptide; MBG =Myocardial blush grade; LVEF = Left ventricular ejection fraction.
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mortality rate at 1 year was 0%, reinfarction rate at 1 year was 1.8%.
4. Discussion
This study investigated the temporal course of hs-CRP levels in
patients who presented with a ﬁrst STEMI and treated with primary
PCI. The principle ﬁndings were as follows. First, higher hs-CRP levels
at presentation are associated with decreased reperfusion success and
these levels remained higher in patients with impaired reperfusion
for up to two months after PCI. Second, hs-CRP at baseline is positively
correlated with ischemia time, although the correlation is not strong,
and together with TIMI ﬂow an independent predictor for myocardial
reperfusion. Third, NT-proBNP levels follow the same trend as hs-CRP
in timewith slightly higher levels in patientswith impaired reperfusion.
Last, LV systolic function was preserved in these STEMI patients andwe
did not observe an association between hs-CRP levels and impaired LV
function and/or long term outcomes.
4.1. Temporal course of hs-CRP
Earlier studies suggested that CRP levels in STEMI patients reached
their peak values between 36 and 42 h after admission [10]. The degree
of inﬂammationmarked by CRPwas associatedwith the degree ofmyo-
cardial necrosis. We indeed observed an association with ischemia time
and impaired reperfusion resulting in increased myocardial necrosis.
The ischemic time might, in part, also explain the higher hs-CRP levels
in these patients at baseline. We also measured hs-CRP at 2 weeks,
7 weeks and 4 months after admission, and in addition to Patti et al.
we report on the temporal course of hs-CRP in STEMI patients [8,9,18,
19]. In addition, we used more sensitive assay to determine the hs-
CRP levels, allowing detection of CRP below 5 mg/l and facilitating the
detection of subtle differences between patients with normal and im-
paired reperfusion. Currently, it remains to be elucidated why hs-CRP
levels continue to remain increased for a substantial long period inTable 3
Univariate and multivariate predictors for impaired reperfusion.
Variable Univariate analy
OR 9
Sex (female) 0.96 0
Age (per year) 1.02 1
hs-CRP level at baseline (per doubling) 1.27 1
NT-pro BNP levels at baseline (per doubling) 1.19 1
Time between symptom onset and catheterization (per hour) 1.18 1
Heart rate (bpm) 1.01 1
Infarct-related artery TIMI ﬂow, preintervention grade 0.75 0
Infarct-related artery TIMI ﬂow, postintervention grade 0.02 0
CK AUC (per doubling) 1.28 1
Myocardial band of CK AUC (per doubling) 1.36 1
Troponin AUC (per doubling) 1.26 1
AUC= area under the curve; Bpm= beats per minute; CI= conﬁdence interval; CK= creatin
natriuretic peptide; OR = odds ratio; TIMI = Thrombolysis in Myocardial Infarction.patients with impaired reperfusion. It may be a consequence of chronic
damage of themicrovasculature of the heart and the inability to recover
quickly due to impaired reperfusion, which causes the liver to continue
producing hs-CRP. Furthermore, inﬂammation plays a key role in
wound healing and scar formation after myocardial infarction [20].
Perhaps this reparative mechanism and the remodeling of the heart
takes longer in patients with impaired reperfusion, which causes the
liver to produce hs-CRP for a longer period. In addition to increased
hs-CRP levels in patientswith impaired reperfusion, the increased levels
of leucocytes, neutrophils, and their ratio in these patients suggest that
these patients have a higher inﬂammatory state. As the signiﬁcant dif-
ference in hs-CRP levels between the impaired and normal reperfusion
persists until 7 weeks after admission, and reperfusion success is nega-
tively correlated with infarct size and positively correlated with left
ventricular ejection fraction, it could be important to continue monitor-
ing hs-CRP levels until at least 7 weeks [21]. Although this study does
not show a direct association between hs-CRP levels and left ventricular
function, monitoring these levels could still be of importance, since
increased hs-CRP levels in STEMI patients with mildly impaired left
ventricular function are associated with adverse cardiovascular events
[22]. However, it remains important to critically consider the possible
function of hs-CRP [23]. Furthermore, in this study they seem to corre-
spond with the kinetics of NT-proBNP, which might still implicate a
potential association between inﬂammation and HF. The ability to eval-
uate hs-CRP levels and to detect subtle differences over time in such a
number of patients is of additional value to previous studies [10].
4.2. hs-CRP and ischemia time as predictors for reperfusion
hs-CRP at baseline is an independent predictor for reperfusion
success. This result is consistent with recent studies showing the associ-
ation of elevated CRP levels at baseline and impaired reperfusion in
STEMI patients [8,9]. However, we studied whether subtle differences
in hs-CRP, measured with a high-sensitive array allow differentiating
between patients with normal and impaired reperfusion. A doubling
in hs-CRP level remains an independent predictor for impaired reperfu-
sion after multivariate adjustment, together with impaired TIMI ﬂow
(postintervention). It might be plausible that these ﬁndings (hs-CRP
and impaired TIMI ﬂow) are linked because of a higher risk of peri-
procedural myocardial infarction in patients with higher CRP levels at
baseline [24].
Previous data suggested that a higher level of hs-CRP (≥3mg/l) is an
independent predictor of long-termclinical outcomes in late-presenting
STEMI patients (i.e. ischemia time ≥ 6 h) [18]. We investigated whether
ischemia time, hsCRP and reperfusion were associated. Ischemia time
waspositively correlatedwith hs-CRP levels, hs-CRPwas negatively cor-
related with reperfusion, and ischemia time was negatively correlated
with reperfusion. Although most of our patients reported a shortersis Multivariate analysis
5% CI p Value OR 95% CI p Value
.58–1.60 0.887 0.76 0.39–1.50 0.431
.00–1.04 0.060 1.01 0.99–1.04 0.351
.08–1.50 0.004 1.24 1.00–1.53 0.042
.06–1.34 0.004 1.10 0.92–1.32 0.304
.08–1.28 0.000 1.05 0.93–1.20 0.429
.00–1.03 0.064 1.01 0.99–1.03 0.240
.62–0.91 0.003 0.79 0.60–1.04 0.100
.01–0.09 0.000 0.04 0.01–0.19 0.000
.11–1.48 0.001 0.99 0.48–2.04 0.975
.16–1.59 0.000 0.90 0.45–1.82 0.773
.11–1.42 0.000 1.15 0.74–1.79 0.536
e kinase; hs-CRP= high sensitivity C-reactive protein; NT-pro BNP=N-terminal probrain
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longer ischemia time than patients with normal reperfusion. However,
ischemia time did not remain an independent predictor for poor reper-
fusion after multivariate adjustment. It is reasonable to assume that
ischemia time inﬂuences hs-CRP levels and thereby indirectly inﬂu-
ences the extent of reperfusion after PCI, and that hs-CRP and TIMI
ﬂow are stronger predictors for reperfusion than ischemia time.
4.3. hs-CRP as surrogate biomarker for the development of HF?
In addition to the measurements of hs-CRP levels at different time
points, we evaluated NT-proBNP levels measured at same time points.
Interestingly, similar to the differences in hs-CRP levels between the
reperfusion groups, NT-proBNP levels were also higher over time in
patients with impaired reperfusion. Currently, many studies report on
the role of inﬂammation in the development of HF [15,25,26]. Because
of the potential association between inﬂammation and HF, we consid-
ered the similarity of the patterns of hs-CRP and NT-proBNP in both
reperfusion groups as an interesting phenomenon. It seemed interest-
ing to investigate in whichway the hs-CRP levels and NT-proBNP levels
correspond to each other, not only at onemoment, but also for a longer
time period, and whether the association between these levels would
differ between reperfusion groups. One way to do this is to calculate
the ratio between these levels. The hs-CRP/NT-proBNP ratio at baseline
in the normal reperfusion group does not differ from the ratio in the
impaired reperfusion group. This is in accordance with the separate
hs-CRP and NT-proBNP levels, because levels of both biomarkers are
higher in the impaired reperfusion group, and implies that a similar pro-
cess is going on in these patient groups. As it seems that the kinetics of
hs-CRP corresponds with the kinetics of NT-proBNP, hs-CRP could be
used as an appropriate biomarker to monitor STEMI patients for the
development of HF since it is likely to represent the same pathophysio-
logical process as NT-proBNP. This ﬁnding, in addition to the increased
leucocyte levels and neutrophil levels, provides a little more insight in
the possible link between inﬂammation and HF development.
4.4. Limitations
Some limitations should be taken into consideration. The GIPS III
study consisted of non-diabetic patients presenting with a ﬁrst STEMI
and as a consequence of rapid primary PCI the myocardial infarct size
was limited and their systolic LV function well preserved. Possibly,
small infarct size and preserved LV-function resulting in limited varia-
tion might explain why we did not observe an association between
hs-CRP and systolic LV-function. Besides, this was a single-center
study in a speciﬁc STEMI population with a high proportion of TIMI-3
ﬂow before intervention and our observations should be carefully
extrapolated to other populations. Furthermore, our study was not
designed to translate hs-CRP levels to clinical decision making and
therefore, our results are not readily applicable to the clinical arena in
terms of relevance for patient management. However, the observed
subtle differences in hs-CRP between reperfusion groups and the phe-
nomenon of resembling the kinetics of NT-proBNP does provide data
that might be of mechanistic insight. Although themechanism between
inﬂammation and reperfusion is not fully elucidated yet, we hope that
we gained a little more insight in this mechanism with our ﬁndings
and that further research could continue with revealing this mecha-
nism. In addition, due to the nature of the condition studied, hs-CRP
was not measured before presentation. These data could have added
more information about the involvement of inﬂammation in plaque
rupture and the time course of hs-CRP.
4.5. Future perspectives
As hs-CRP is just one marker in the inﬂammation network, it is
necessary to investigate more participants in the inﬂammatory cascade.It is interesting to dig further into the mechanisms of other inﬂam-
matory markers and to evaluate their course after intervention for
STEMI. Currently, we see a difference in biomarker levels between
patients with impaired and normal reperfusion for a longer time period.
As the current follow-up is not very long, we could just speculate on
longer term outcomes. In a few years, we have more information
about these patients and are hopefully able to state whether differences
in biomarker level inﬂuences long term outcomes in patients with
impaired and normal reperfusion.
5. Conclusion
Higher hs-CRP levels at presentation are associated with lower
reperfusion success and higher NT-proBNP levels. Impaired reperfusion
is also associated with long-term higher hs-CRP levels compared to
optimal reperfusion. Advancing our understanding of the temporal
course of inﬂammatorymarkers in STEMI provide new insights required
to further develop novel strategies of treatment.
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